New Risk • May 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€55.4m market cap, or US$64.3m). Valuation Update With 7 Day Price Move • Apr 23
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to €5.80, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 27x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 97% over the past three years. 공시 • Apr 18
Labiana Health, S.A. to Report Fiscal Year 2025 Results on Apr 21, 2026 Labiana Health, S.A. announced that they will report fiscal year 2025 results on Apr 21, 2026 New Risk • Apr 13
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€38.7m market cap, or US$45.5m). Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €4.44, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 25x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 44% over the past three years. Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €5.50, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 25x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 68% over the past three years. New Risk • Feb 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (4.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€31.9m market cap, or US$37.9m). 공시 • Oct 29
Labiana Health, S.A. to Report Q2, 2025 Results on Oct 30, 2025 Labiana Health, S.A. announced that they will report Q2, 2025 results on Oct 30, 2025 New Risk • Sep 03
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 6.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Share price has been highly volatile over the past 3 months (6.0% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€31.0m market cap, or US$36.1m). New Risk • Jul 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Share price has been volatile over the past 3 months (4.8% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€23.5m market cap, or US$27.6m). 공시 • May 27
Labiana Health, S.A., Annual General Meeting, Jun 26, 2025 Labiana Health, S.A., Annual General Meeting, Jun 26, 2025. Location: av europa 34d, pozuelo de alarcon, madrid Spain 공시 • Apr 13
Labiana Health, S.A. to Report Fiscal Year 2024 Results on Apr 22, 2025 Labiana Health, S.A. announced that they will report fiscal year 2024 results on Apr 22, 2025 Breakeven Date Change • Nov 19
Forecast breakeven date moved forward to 2024 The 2 analysts covering Labiana Health previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €550.0k in 2024. Earnings growth of 99% is required to achieve expected profit on schedule. New Risk • Jun 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.0% average weekly change). Market cap is less than US$100m (€16.0m market cap, or US$17.3m). New Risk • Sep 29
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €9.24m (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Market cap is less than US$10m (€9.24m market cap, or US$9.78m). 
